Is evantumumab already on the market in China?

Amivantamab (amivantamab-vmjw), as a new drug, has many potential advantages and application prospects. It is a bispecific antibody that targets both EGFR and MET, two proteins that play key roles in non-small cell lung cancer. By targeting these two targets simultaneously, evantumumab can effectively inhibit tumor growth and metastasis and reduce the occurrence of drug resistance.

In clinical trials, evantumumab has shown significant efficacy. This drug can provide a new treatment option for patients with locally advanced or metastatic non-small cell lung cancer who have EGFR exon 20 insertion mutations. Evantumumab can improve survival and quality of life in patients whose disease has progressed after platinum-based chemotherapy.

However, it should be noted that evantumumab is not suitable for all patients with non-small cell lung cancer. It mainly targets patients with EGFR exon 20 insertion mutations, which are uncommon among patients with non-small cell lung cancer. Therefore, more treatment options still need to be explored and developed for patients with other types of NSCLC.

Also, like all medications, evantuzumab has some side effects. Based on data from clinical trials, some patients may experience infusion-related reactions, but this can be controlled with appropriate measures, such as adjusting the dose or changing the infusion method. Overall, the safety and tolerability of evantuzumab was manageable, and side effects were acceptable compared with the therapeutic benefits.

Although evantumumab is not yet commercially available in China, with its success and widespread application in overseas markets, more clinical data and practical application experience will be accumulated to provide better treatment options for Chinese patients.